Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard-dose azacitidine.
Ogawa S, Sakamoto T, Matsuoka R, Ishitsuka K, Ogino Y, Sootome A, Makishima K, Yoshida C, Ito Y, Shimizu S, Suyama T, Shinagawa A, Ito T, Obara N, Kusakabe M, Sakata-Yanagimoto M, Miyazaki Y, Nannya Y, Chiba S.
Ogawa S, et al. Among authors: ito y, ito t.
Cancer Rep (Hoboken). 2024 Jan;7(1):e1938. doi: 10.1002/cnr2.1938. Epub 2023 Nov 28.
Cancer Rep (Hoboken). 2024.
PMID: 38014499
Free PMC article.